We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia.
- Authors
Takahashi, N.; Wakita, H.; Miura, M.; Scott, S. A.; Nishii, K.; Masuko, M.; Sakai, M.; Maeda, Y.; Ishige, K.; Kashimura, M.; Fujikawa, K.; Fukazawa, M.; Katayama, T.; Monma, F.; Narita, M.; Urase, F.; Furukawa, T.; Miyazaki, Y.; Katayama, N.; Sawada, K.
- Abstract
Despite the outstanding results generally obtained with imatinib mesylate (IM) in the treatment of chronic myeloid leukemia (CML), some patients show a poor molecular response. To evaluate the relationship between steady-state trough plasma IM concentration (IM-Cmin) and clinical response in CML patients, we integrated data from six independent Japanese studies. Among 254 CML patients, the mean IM-Cmin was 1,010.5 ng/ml. Importantly, IM-Cmin was significantly higher in patients who achieved a major molecular response (MMR) than in those who did not (P = 0.002). Multivariate analysis showed that an MMR was associated with both age (odds ratio (OR) = 0.97 (0.958-0.995); P = 0.0153) and with IM-Cmin (OR = 1.0008 (1.0003-1.0015); P = 0.0044). Given that patients with IM-Cmin values >1,002 ng/ml had a higher probability of achieving an MMR in our large cohort (P = 0.0120), the data suggest that monitoring of IM levels in plasma may improve the efficacy of IM therapy for CML patients.
- Subjects
IMATINIB; METHANESULFONATES; TREATMENT of chronic myeloid leukemia; PHARMACOKINETICS; BLOOD plasma; DRUG efficacy; MULTIVARIATE analysis
- Publication
Clinical Pharmacology & Therapeutics, 2010, Vol 88, Issue 6, p809
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1038/clpt.2010.186